Sara Willa Ernst

The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?

Scott Gottlieb, a former FDA commissioner, said a recent decision by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices’ to change its recommendation for when children should receive the hepatitis B vaccine is another sign of the ACIP’s diminished credibility as a scientific authority. 

The Friends of Cancer Research annual meeting, to be held Nov. 4 in Washington, DC, will focus on three questions facing the field of oncology clinical trial design.

Scientists, health care professionals, and supporters will take to the streets on Nov. 5, calling for Congress to remove Robert F. Kennedy Jr. from his position as Secretary of Health and Human Services. 

A court filing by Thomas Nagy Jr., deputy assistant secretary for Human Resources and chief human capital officer at HHS, claims that his department can proceed with the 982 RIFs it issued two weeks ago, despite a judge’s temporary order freezing the notices issued by two dozen federal agencies since the government shutdown that began on Oct 1. 

NIH has published a policy that prohibits U.S. researchers and NIH grant recipients working with human biospecimens to share this data with “countries of concern.” That list includes China (including Hong Kong and Macau), Russia, Iran, North Korea, Cuba, and Venezuela. 

Chris Biggar, a 34-year-old from Ohio, had just landed his dream job working in R&D when he was diagnosed with stage 4 colon cancer. 

NCI has released the names of the members of the newly formed ad hoc Working Group on Extramural Research Concepts and Programs. The group will perform the peer review functions of the now-defunct Board of Scientific Advisors.

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 

The National Cancer Advisory Board approved five reissue concepts at a meeting Sept. 4. 

A federal judge ruled that the Trump Administration’s move to cut research funding to Harvard University was illegal—restoring more than $2 billion and all future grants to the institution. 

FDA is shortening its timeline for publicizing Complete Response Letters, pledging to make them available to the public “promptly” after sponsors receive notice. 

Phil and Penny Knight made a record-setting $2 billion gift to OHSU Knight Cancer Institute.

Earlier this year, amid efforts by the Trump administration to reduce the federal workforce, Lakshmi Grama decided to take early retirement from NCI.

Those anxiously anticipating the release of the U.S. News & World Report‘s evaluation of cancer hospitals will find one intriguing change.

The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.

On July 4, President Donald Trump signed into law “The One Big Beautiful Bill Act,” which is expected to deal a massive blow to Medicaid coverage and leave millions without insurance by instituting a work requirement for beneficiaries. 

The FDA Oncologic Drugs Advisory Committee July 17 recommended against approval of a Blenrep-based regimen for the treatment of relapsed or refractory multiple myeloma, citing unacceptable rates of ocular toxicity and overall poor tolerability of the drug.